This trial is active, not recruiting.

Conditions treatment resistant depression, depressive disorder
Treatment libra deep brain stimulation system
Sponsor St. Jude Medical
Start date June 2011
End date June 2017
Trial size 40 participants
Trial identifier NCT01801319, C-08-07, Health Canada 148956


This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety, efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate Gyrus Deep Brain Stimulation (SCG DBS) for participants with Treatment-Resistant Depression (TRD). A total of 40 eligible participants will be randomized to four treatment sequences (10 participants per sequence). Each participant will be treated over a 6-month period with active or sham stimulation in which both the participants and the attending psychiatrists will be blinded to treatment allocation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model crossover assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
(Active Comparator)
Libra Deep Brain Stimulation System is implanted and activated post implantation
libra deep brain stimulation system
(Sham Comparator)
The Libra DBS System is implanted and not activated
libra deep brain stimulation system

Primary Outcomes

Primary Efficacy: Changes in the Hamilton Depression Rating Scale-17
time frame: 3 and 6 months

Secondary Outcomes

The incidence of all adverse events
time frame: 6 months
Showing SCG-DBS significantly increases health related quality of life compared to sham stimulation in patients with TRD
time frame: 6 months

Eligibility Criteria

Male or female participants from 21 years up to 70 years old.

Inclusion Criteria: 1. Men and women (non-pregnant) ages 21-70 years; 2. Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by DSM-IV-TR criteria; 3. First episode onset before age 45; 4. Current episode > 12 months duration; 5. In the current episode: Documented resistance (i.e. persistence of the major depressive episode) to a minimum of 4 adequate depression treatments from at least 3 different treatment categories (e.g. SSRI's, SNRI's, TCA's, MAO-inhibitors, Mirtazipine, Nefazodone, Trazodone, Bupropion, lithium augmentation, thyroid augmentation, ECT); Adequacy of treatments as defined by a score of at least 3 according to the amended Antidepressant Treatment History Form (ATHF) criteria; 6. Hamilton Depression Rating Scale (HDRS) of > 20 at 3 separate baseline visits, rated by 2 separate psychiatrists, Baseline 2 and Baseline 3 HDRS scores cannot improve ≥ 25%; Exclusion Criteria: 1. A diagnosis of a bipolar I or bipolar II disorder by DSM-IV-TR criteria; 2. Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-IV-TR criteria, derived from the Cluster B Personality. 3. In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis; 4. Has an intracranial Central Nervous System (CNS) disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication (e.g., Parkinson's Disease, migraine, stroke, Huntington's, head trauma, etc.) with exception to non-migraine headaches; 5. Has been diagnosed with fibromyalgia or has a current condition which requires chronic pain narcotic usage (e.g. morphine, methadone); 6. Has been currently diagnosed with chronic fatigue syndrome; 7. Substantial suicidal risk as defined by (1) a current plan and intent, (2) clinician judgment that there is a clear immediate intent for self-harm, (3) more than 3 suicide attempts within the last 12 months; 8. Co-morbid obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, bulimia or anorexia nervosa if previously present, must be in remission for 6 months as defined by DSM-IV-TR criteria, derived from the MINI; 9. Alcohol, medication, or illegal substance dependence within last 12 months; 10. Advanced cardiovascular disease which renders anesthesia and surgery as unsafe as determined by neurosurgeon; 11. Plans to use diathermy; 12. Have any metallic implants in the brain such as aneurysm clips or cochlear implants; 13. Currently participating in another investigational device, drug or surgical trial.

Additional Information

Official title A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
Principal investigator Sidney Kennedy, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by St. Jude Medical.